QQQ   315.68 (+0.95%)
AAPL   162.36 (+0.99%)
MSFT   284.05 (+1.26%)
META   207.84 (+1.21%)
GOOGL   100.89 (-0.49%)
AMZN   102.00 (+1.75%)
TSLA   195.28 (+0.72%)
NVDA   273.83 (+1.48%)
NIO   10.46 (+6.41%)
BABA   103.38 (+3.46%)
AMD   97.88 (+1.86%)
T   19.08 (+0.42%)
F   12.29 (+1.99%)
MU   63.09 (-0.71%)
CGC   1.76 (-2.76%)
GE   94.05 (-0.01%)
DIS   98.10 (+1.27%)
AMC   4.97 (-0.60%)
PFE   40.38 (+0.32%)
PYPL   74.39 (+0.28%)
NFLX   338.43 (+1.93%)
QQQ   315.68 (+0.95%)
AAPL   162.36 (+0.99%)
MSFT   284.05 (+1.26%)
META   207.84 (+1.21%)
GOOGL   100.89 (-0.49%)
AMZN   102.00 (+1.75%)
TSLA   195.28 (+0.72%)
NVDA   273.83 (+1.48%)
NIO   10.46 (+6.41%)
BABA   103.38 (+3.46%)
AMD   97.88 (+1.86%)
T   19.08 (+0.42%)
F   12.29 (+1.99%)
MU   63.09 (-0.71%)
CGC   1.76 (-2.76%)
GE   94.05 (-0.01%)
DIS   98.10 (+1.27%)
AMC   4.97 (-0.60%)
PFE   40.38 (+0.32%)
PYPL   74.39 (+0.28%)
NFLX   338.43 (+1.93%)
QQQ   315.68 (+0.95%)
AAPL   162.36 (+0.99%)
MSFT   284.05 (+1.26%)
META   207.84 (+1.21%)
GOOGL   100.89 (-0.49%)
AMZN   102.00 (+1.75%)
TSLA   195.28 (+0.72%)
NVDA   273.83 (+1.48%)
NIO   10.46 (+6.41%)
BABA   103.38 (+3.46%)
AMD   97.88 (+1.86%)
T   19.08 (+0.42%)
F   12.29 (+1.99%)
MU   63.09 (-0.71%)
CGC   1.76 (-2.76%)
GE   94.05 (-0.01%)
DIS   98.10 (+1.27%)
AMC   4.97 (-0.60%)
PFE   40.38 (+0.32%)
PYPL   74.39 (+0.28%)
NFLX   338.43 (+1.93%)
QQQ   315.68 (+0.95%)
AAPL   162.36 (+0.99%)
MSFT   284.05 (+1.26%)
META   207.84 (+1.21%)
GOOGL   100.89 (-0.49%)
AMZN   102.00 (+1.75%)
TSLA   195.28 (+0.72%)
NVDA   273.83 (+1.48%)
NIO   10.46 (+6.41%)
BABA   103.38 (+3.46%)
AMD   97.88 (+1.86%)
T   19.08 (+0.42%)
F   12.29 (+1.99%)
MU   63.09 (-0.71%)
CGC   1.76 (-2.76%)
GE   94.05 (-0.01%)
DIS   98.10 (+1.27%)
AMC   4.97 (-0.60%)
PFE   40.38 (+0.32%)
PYPL   74.39 (+0.28%)
NFLX   338.43 (+1.93%)
NASDAQ:VIVO

Meridian Bioscience - VIVO Stock Forecast, Price & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
Add
Compare
Today's Range
$33.93
$34.02
50-Day Range
$33.00
$33.97
52-Week Range
$20.35
$34.38
Volume
6.42 million shs
Average Volume
973,737 shs
Market Capitalization
$1.50 billion
P/E Ratio
35.02
Dividend Yield
N/A
Price Target
$34.00

Meridian Bioscience MarketRank™ Forecast

Analyst Rating
Hold
2.00 Rating Score
Upside/​Downside
0.1% Upside
$34.00 Price Target
Short Interest
N/A
Dividend Strength
N/A
Sustainability
-1.21
Upright™ Environmental Score
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
N/A

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.36 out of 5 stars

Medical Sector

969th out of 1,009 stocks

Diagnostic Substances Industry

13th out of 14 stocks


VIVO stock logo

About Meridian Bioscience (NASDAQ:VIVO) Stock

Meridian Bioscience, Inc. engages in the development, production, sale, and distribution of diagnostic products. Its platforms include molecular, immunoassay, urea breath, and blood chemistry. It operates through the Diagnostics and Life Science segments. The Diagnostics segment consists of manufacturing operations for infectious disease and blood chemistry products and the sale and distribution of diagnostics products domestically and abroad. The Life Science segment distributes bulk antigens, antibodies, polymerase chain reaction/ quantitative PCR reagents, nucleotides, competent cells, and bioresearch reagents used by researchers, agri-bio companies, and other diagnostic manufacturing companies. The company was founded by William J. Motto in 1976 and is headquartered in Cincinnati, OH.

Receive VIVO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Meridian Bioscience and its competitors with MarketBeat's FREE daily newsletter.

VIVO Stock News Headlines

A 100% Win Rate In 2022…
The next 10 minutes could change your life. We've recorded a special sit-down interview with a reclusive millionaire who details how he's closed out winning trade after winning trade throughout the volatility of 2022. In fact, he hasn't closed a single losing trade since 2016. Sounds impossible? It's not - and he'll prove it to you. pixel
Phoenix Union Bioscience High School
A 100% Win Rate In 2022…
The next 10 minutes could change your life. We've recorded a special sit-down interview with a reclusive millionaire who details how he's closed out winning trade after winning trade throughout the volatility of 2022. In fact, he hasn't closed a single losing trade since 2016. Sounds impossible? It's not - and he'll prove it to you. pixel
Meridian Biosciences: Why I Moved On But May Go Back In
Meridian Bioscience (VIVO) Q4 Earnings Surpass Estimates
BellRing Brands (BRBR) Beats Q4 Earnings Estimates
Meridian Bioscience, Inc. (VIVO)
VIVO Meridian Bioscience, Inc.
SHAREHOLDER UPDATE: Halper Sadeh LLC Investigates VIVO, SAVE, AAWW, MNRL
Meridian Bioscience Inc
Meridian Bioscience (VIVO) Meets Q3 Earnings Estimates
See More Headlines
Receive VIVO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Meridian Bioscience and its competitors with MarketBeat's FREE daily newsletter.

VIVO Company Calendar

Last Earnings
11/12/2021
Today
3/30/2023
Fiscal Year End
9/30/2023

Industry, Sector and Symbol

Industry
Diagnostic substances
Sub-Industry
Health Care Supplies
Sector
Medical
Current Symbol
NASDAQ:VIVO
CUSIP
58958410
Employees
702
Year Founded
1977

Price Target and Rating

Average Stock Price Forecast
$34.00
High Stock Price Forecast
$34.00
Low Stock Price Forecast
$34.00
Forecasted Upside/Downside
+0.1%
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
2 Analysts

Profitability

Net Income
$42.46 million
Pretax Margin
16.31%

Debt

Sales & Book Value

Annual Sales
$333.02 million
Cash Flow
$1.78 per share
Book Value
$8.41 per share

Miscellaneous

Free Float
42,996,000
Market Cap
$1.50 billion
Optionable
Optionable
Beta
0.23

Social Links


Key Executives

  • John Patrick Kenny
    Chief Executive Officer & Executive Director
  • Andrew S. KitzmillerAndrew S. Kitzmiller
    Chief Financial Officer & Executive Vice President
  • Julie Smith
    Chief Accounting Officer, Senior VP & Controller
  • Emerson C. Moser
    Senior Vice President & General Counsel
  • Lourdes WeltzienLourdes Weltzien
    Executive Vice President-Life Science













VIVO Stock - Frequently Asked Questions

Should I buy or sell Meridian Bioscience stock right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Meridian Bioscience in the last twelve months. There are currently 2 hold ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" VIVO shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in VIVO, but not buy additional shares or sell existing shares.
View VIVO analyst ratings
or view top-rated stocks.

What is Meridian Bioscience's stock price forecast for 2023?

2 brokers have issued 1 year price targets for Meridian Bioscience's shares. Their VIVO share price forecasts range from $34.00 to $34.00. On average, they anticipate the company's share price to reach $34.00 in the next twelve months. This suggests a possible upside of 0.1% from the stock's current price.
View analysts price targets for VIVO
or view top-rated stocks among Wall Street analysts.

How were Meridian Bioscience's earnings last quarter?

Meridian Bioscience, Inc. (NASDAQ:VIVO) issued its quarterly earnings data on Friday, November, 12th. The company reported $0.24 EPS for the quarter, topping analysts' consensus estimates of $0.21 by $0.03. The firm had revenue of $76.20 million for the quarter, compared to analysts' expectations of $68.40 million. Meridian Bioscience had a net margin of 12.70% and a trailing twelve-month return on equity of 16.74%. During the same quarter in the previous year, the firm posted $0.19 earnings per share.

What ETFs hold Meridian Bioscience's stock?

ETFs with the largest weight of Meridian Bioscience (NASDAQ:VIVO) stock in their portfolio include AltShares Event-Driven ET (EVNT) and AltShares Merger Arbitrage ETF (ARB).WisdomTree U.S. SmallCap Fund (EES).

What is Jack Kenny's approval rating as Meridian Bioscience's CEO?

7 employees have rated Meridian Bioscience Chief Executive Officer Jack Kenny on Glassdoor.com. Jack Kenny has an approval rating of 56% among the company's employees. This puts Jack Kenny in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Meridian Bioscience own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Meridian Bioscience investors own include AbbVie (ABBV), NVIDIA (NVDA), Advanced Micro Devices (AMD), Micron Technology (MU), Pfizer (PFE), AT&T (T), Gilead Sciences (GILD), Amgen (AMGN), Alibaba Group (BABA) and Tesla (TSLA).

What is Meridian Bioscience's stock symbol?

Meridian Bioscience trades on the NASDAQ under the ticker symbol "VIVO."

Who are Meridian Bioscience's major shareholders?

Meridian Bioscience's stock is owned by a variety of institutional and retail investors. Top institutional investors include Renaissance Technologies LLC (4.77%), Dimensional Fund Advisors LP (4.07%), Alliancebernstein L.P. (2.98%), Geode Capital Management LLC (2.00%), AQR Arbitrage LLC (1.83%) and Morgan Stanley (1.47%). Insiders that own company stock include Andrew S Kitzmiller, Anthony P Bihl III, Bryan T Baldasare, John Mccune Jr Rice, John P Kenny and Lourdes Weltzien.
View institutional ownership trends
.

What is Meridian Bioscience's stock price today?

One share of VIVO stock can currently be purchased for approximately $33.97.

How much money does Meridian Bioscience make?

Meridian Bioscience (NASDAQ:VIVO) has a market capitalization of $1.50 billion and generates $333.02 million in revenue each year. The company earns $42.46 million in net income (profit) each year or $0.97 on an earnings per share basis.

How many employees does Meridian Bioscience have?

The company employs 702 workers across the globe.

Does Meridian Bioscience have any subsidiaries?
The following companies are subsidiares of Meridian Bioscience: Exalenz Bioscience.
Read More
How can I contact Meridian Bioscience?

Meridian Bioscience's mailing address is 3471 RIVER HILLS DRIVE, CINCINNATI OH, 45244. The official website for the company is www.meridianbioscience.com. The company can be reached via phone at (513) 271-3700, via email at mbi@meridianbioscience.com, or via fax at 513-271-3762.

This page (NASDAQ:VIVO) was last updated on 3/30/2023 by MarketBeat.com Staff